Preexisting Vaccinia Virus Immunity Decreases SIV-Specific Cellular Immunity but Does Not Diminish Humoral Immunity and Efficacy of a DNA/MVA Vaccine-Reference-Cited by-同舟云学术

Preexisting Vaccinia Virus Immunity Decreases SIV-Specific Cellular Immunity but Does Not Diminish Humoral Immunity and Efficacy of a DNA/MVA Vaccine

Published:2010-11-12 Issue:12 Volume:185 Page:7262-7273
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Kannanganat Sunil,Nigam Pragati,Velu Vijayakumar,Earl Patricia L.,Lai Lilin,Chennareddi Lakshmi,Lawson Benton,Wilson Robert L.,Montefiori David C.,Kozlowski Pamela A.,Moss Bernard,Robinson Harriet L.,Amara Rama Rao

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference61 articles.

1. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

2. Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine

3. Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines

4. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

5. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytomegalovirus-vectored COVID-19 vaccines elicit neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.2) in mice;Microbiology Spectrum;2023-12-12

2. A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection;Molecular Therapy - Methods & Clinical Development;2023-12

3. Advances in vaccinia virus-based vaccine vectors, with applications in flavivirus vaccine development;Vaccine;2022-11

4. V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques;Frontiers in Immunology;2022-07-22

5. Viral Delivery of IL-7 Is a Potent Immunotherapy Stimulating Innate and Adaptive Immunity and Confers Survival in Sepsis Models;The Journal of Immunology;2022-07-01